-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Pg6B6g/ZOQvdM8dt+x90+zT+cB/b4BLb9AtATVLfTbyiYigcIceGcfCJ50jQG+bd 4xfKZIP9aImbWDr1GHgbog== 0000062391-99-000010.txt : 19991224 0000062391-99-000010.hdr.sgml : 19991224 ACCESSION NUMBER: 0000062391-99-000010 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19991223 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-48751 FILM NUMBER: 99779456 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 2: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G/A 1 AMENDMENT NO. 2 TO SCHEDULE 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 04033A 10 0 ----------------- (CUSIP Number) December 15, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ x ] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== Page 1 of 8 Exhibit Index is located at page 7 2 CUSIP No. 04033A 10 0 ___________________________________________________________________________ 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 3,004,436 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 3,004,436 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 3,004,436 by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 12.0% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ 3 CUSIP No. 04033A 10 0 13G ___________________________________________________________________________ 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 ___________________________________________________________________________ 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] ___________________________________________________________________________ 3) SEC Use Only ___________________________________________________________________________ 4) Citizenship or Place of Organization Delaware ___________________________________________________________________________ 5) Sole Voting Power 3,004,436 Number of ____________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 3,004,436 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 ___________________________________________________________________________ 9) Aggregate Amount Beneficially Owned 3,004,436 by Each Reporting Person ___________________________________________________________________________ 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares ___________________________________________________________________________ 11) Percent of Class Represented 12.0% by Amount in Row (9) ___________________________________________________________________________ 12) Type of Reporting Person CO ___________________________________________________________________________ 4 CUSIP No. 04033A 10 0 13G This Amendment No. 2 to the Statement on Schedule 13G of Aventis Pharmaceuticals Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware corporation, is filed solely to reflect the change of name of Hoechst Marion Roussel, Inc., to Aventis Pharmaceuticals Inc. The following items of the Statement on Schedule 13G are hereby amended to read as follows: ITEM 2(a). NAME OF PERSON FILING: - ---------- ---------------------- Aventis Pharmaceuticals Inc. HMR Pharma, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: - ---------- ------------------------------------------------------------ Aventis Pharmaceuticals Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 HMR Pharma, Inc. 10236 Marion Park Drive Kansas City, Missouri 64137-1405 ITEM 2(c). CITIZENSHIP: - ---------- ------------ Delaware As To Both Aventis Pharmaceuticals Inc. And HMR Pharma, Inc. ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 11/08/99 3,004,436 Shares Of Series B Convertible Preferred Stock. The Shares Are Convertible Into Common Stock On A Share-For-Share Basis. (b): PERCENT OF CLASS: 12.0% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 3,004,436 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,004,436 (iv) Shared power to dispose or to direct the 0 disposition of: 5 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. December 22, 1999 --------------------------------- (Date) HMR PHARMA, INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Assistant Secretary --------------------------------- (Name/Title) 6 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. December 22, 1999 --------------------------------- (Date) Aventis Pharmaceuticals INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 7 CUSIP No. 04033A 10 0 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated December 8 22, 1999, by and between Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. 8 CUSIP No. 04033A 10 0 13G EXHIBIT 99.A AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. Date: December 22, 1999 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Assistant Secretary -----END PRIVACY-ENHANCED MESSAGE-----